Inflammation and tumor progression: signaling pathways and targeted intervention

Abstract

Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses tumor progression, potentially displaying opposing effects on therapeutic outcomes. Chronic inflammation facilitates tumor progression and treatment resistance, whereas induction of acute inflammatory reactions often stimulates the maturation of dendritic cells (DCs) and antigen presentation, leading to anti-tumor immune responses. In addition, multiple signaling pathways, such as nuclear factor kappa B (NF-kB), Janus kinase/signal transducers and activators of transcription (JAK-STAT), toll-like receptor (TLR) pathways, cGAS/STING, and mitogen-activated protein kinase (MAPK); inflammatory factors, including cytokines (e.g., interleukin (IL), interferon (IFN), and tumor necrosis factor (TNF)-α), chemokines (e.g., C-C motif chemokine ligands (CCLs) and C-X-C motif chemokine ligands (CXCLs)), growth factors (e.g., vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β), and inflammasome; as well as inflammatory metabolites including prostaglandins, leukotrienes, thromboxane, and specialized proresolving mediators (SPM), have been identified as pivotal regulators of the initiation and resolution of inflammation. Nowadays, local irradiation, recombinant cytokines, neutralizing antibodies, small-molecule inhibitors, DC vaccines, oncolytic viruses, TLR agonists, and SPM have been developed to specifically modulate inflammation in cancer therapy, with some of these factors already undergoing clinical trials. Herein, we discuss the initiation and resolution of inflammation, the crosstalk between tumor development and inflammatory processes. We also highlight potential targets for harnessing inflammation in the treatment of cancer.

References 906

1. 1.

   Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394-424.

   Not in our library10.3322/caac.21492

2. 2.

   Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299-309.

   Not in our library10.1038/s41586-019-1730-1

3. 3.
   The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects · 2020

   No notice
4. 4.

   Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-899.

   Not in our library10.1016/j.cell.2010.01.025

5. 5.

   Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.

   Not in our library10.1038/nature01322

6. 6.

   Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat. Rev. Clin. Oncol. 2015;12:584-596.

   Not in our library10.1038/nrclinonc.2015.105

7. 7.

   Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology. 2002;16:217-226.

   Not in our library

8. 8.

   Schaue D, et al. Radiation and inflammation. Semin Radiat. Oncol. 2015;25:4-10.

   Not in our library10.1016/j.semradonc.2014.07.007

9. 9.

   Guthrie GJ, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit. Rev. Oncol. Hematol. 2013;88:218-230.

   Not in our library10.1016/j.critrevonc.2013.03.010

10. 10.

    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.

    Not in our library10.1016/s0140-6736(00)04046-0

11. 11.

    Punt S, et al. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency. Cancer Immunol. Immunother. 2016;65:393-403.

    Not in our library10.1007/s00262-016-1805-x

12. 12.

    Elinav E, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer. 2013;13:759-771.

    Not in our library10.1038/nrc3611

13. 13.

    Ma Y, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38:729-741.

    Not in our library10.1016/j.immuni.2013.03.003

14. 14.

    Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140:871-882.

    Not in our library10.1016/j.cell.2010.02.029

15. 15.

    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-444.

    Not in our library10.1038/nature07205

16. 16.

    Ritter B, Greten FR. Modulating inflammation for cancer therapy. J. Exp. Med. 2019;216:1234-1243.

    Not in our library10.1084/jem.20181739

17. 17.

    Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493-e503.

    Not in our library10.1016/s1470-2045(14)70263-3

18. 18.

    Cuzick J, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501-507.

    Not in our library10.1016/s1470-2045(09)70035-x

19. 19.

    Rothwell PM, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31-41.

    Not in our library10.1016/s0140-6736(10)62110-1

20. 20.

    Cuzick J, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann. Oncol. 2015;26:47-57.

    Not in our library10.1093/annonc/mdu225

21. 21.

    Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J. Clin. Oncol. 2005;23:8606-8612.

    Not in our library10.1200/jco.2005.02.7045

22. 22.

    Maisonneuve P, Lowenfels AB. Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005;353:952-954.

    Not in our library10.1056/nejmc051738

23. 23.

    Bonovas S, Nikolopoulos G, Sitaras NM. Statins and reduced risk of hepatocellular carcinoma in patients with hepatitis C virus infection: further evidence is warranted. J. Clin. Oncol. 2013;31:4160.

    Not in our library10.1200/jco.2013.50.9208

24. 24.

    Hao H, et al. Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Lett. 2011;309:85-94.

    Not in our library10.1016/j.canlet.2011.05.020

25. 25.

    Li Y, et al. Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene. 2011;30:3887-3899.

    Not in our library10.1038/onc.2011.112

26. 26.

    Wang Z, et al. Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells. Cancer Lett. 2015;364:118-124.

    Not in our library10.1016/j.canlet.2015.04.030

27. 27.

    Mulder WJM, Gnjatic S. Cancer immunotherapy: from local to global. Nat. Nanotechnol. 2017;12:840-841.

    Not in our library10.1038/nnano.2017.196

28. 28.
    Targeting immune cells for cancer therapy · 2019

    No notice
29. 29.

    Davila ML, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 2014;6:224ra225.

    Not in our library10.1126/scitranslmed.3008226

30. 30.

    Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol. Ther. Oncolytics. 2016;3:16011.

    Not in our library10.1038/mto.2016.11

31. 31.

    Dorward DA, Lucas CD, Rossi AG, Haslett C, Dhaliwal K. Imaging inflammation: molecular strategies to visualize key components of the inflammatory cascade, from initiation to resolution. Pharm. Ther. 2012;135:182-199.

    Not in our library10.1016/j.pharmthera.2012.05.006

32. 32.

    Sun SC. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat. Rev. Immunol. 2017;17:545-558.

    Not in our library10.1038/nri.2017.52

33. 33.

    Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428-435.

    Not in our library10.1038/nature07201

34. 34.

    Kono H, Rock KL. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 2008;8:279-289.

    Not in our library10.1038/nri2215

35. 35.

    Nathan C. Points of control in inflammation. Nature. 2002;420:846-852.

    Not in our library10.1038/nature01320

36. 36.

    Headland SE, Norling LV. The resolution of inflammation: Principles and challenges. Semin. Immunol. 2015;27:149-160.

    Not in our library10.1016/j.smim.2015.03.014

37. 37.

    Wright HL, Moots RJ, Bucknall RC, Edwards SW. Neutrophil function in inflammation and inflammatory diseases. Rheumatology. 2010;49:1618-1631.

    Not in our library10.1093/rheumatology/keq045

38. 38.

    Savill JS, et al. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J. Clin. Invest. 1989;83:865-875.

    Not in our library10.1172/jci113970

39. 39.

    Rossi AG, et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med. 2006;12:1056-1064.

    Not in our library10.1038/nm1468

40. 40.

    Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Disco. 2004;3:401-416.

    Not in our library10.1038/nrd1383

Cited by papers we hold 25

• Microbiota dysbiosis impact on the metabolism of T3 and T4 hormones and its association with thyroid cancer · 2025
  Not checked
• Immunomodulatory potential of exopolysaccharides from Lactiplantibacillus plantarum YY-112 · 2025
  Not checked
• Efficacy prediction of neoadjuvant cadonilimab plus FLOT therapy for advanced gastric cancer: a study based on body composition changes · 2025
  Not checked
• Free radicals and their impact on health and antioxidant defenses: a review · 2025
  No notice
• The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis · 2025
  No notice
• Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications · 2025
  No notice
• Tumor biomarkers for diagnosis, prognosis and targeted therapy · 2024
  No notice
• Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets · 2024
  No notice
• Intratumoural microbiota: a new frontier in cancer development and therapy · 2024
  No notice
• Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks · 2024
  No notice
• Protein neddylation and its role in health and diseases · 2024
  No notice
• The JAK-STAT pathway: from structural biology to cytokine engineering · 2024
  Corrected
• Cross-talk of inflammation and cellular senescence: a new insight into the occurrence and progression of osteoarthritis · 2024
  No notice
• Theranostic Fluorescent Probes · 2024
  No notice
• Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response · 2023
  Not checked
• γδ T cells: origin and fate, subsets, diseases and immunotherapy · 2023
  No notice
• The roles of E3 ubiquitin ligases in cancer progression and targeted therapy · 2023
  No notice
• Macrophages in immunoregulation and therapeutics · 2023
  No notice
• Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy · 2023
  No notice
• Anti-inflammatory activity of Sabicea brevipes Wernharm (Rubiaceae) · 2022
  Not checked

and 5 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.